ERBB2 and gastroesophageal junction adenocarcinoma: In the phase III SPOTLIGHT trial (NCT03504397), which enrolled 565 patients with CLDN18.2-positive, HER2-negative gastric or GEJ adenocarcinoma, zolbetuximab combined with mFOLFOX6 significantly improved progression-free survival (PFS: 10.6 vs. 8.7 months) and OS (18.2 vs. 15.5 months) compared to chemotherapy alone.